Jeffrey S Weber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4771236/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nature Reviews Drug Discovery, 2022, 21, 495-508.	46.4	120
2	Deep Learning and Pathomics Analyses Reveal Cell Nuclei as Important Features for Mutation Prediction of BRAF-Mutated Melanomas. Journal of Investigative Dermatology, 2022, 142, 1650-1658.e6.	0.7	22
3	Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont <i>et al</i> . , 2022, 10, e004347.		0
4	American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach. Endocrine Practice, 2022, 28, 719-731.	2.1	12
5	Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?. Journal of Neuro-Oncology, 2022, 158, 471-480.	2.9	5
6	Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. Clinical Cancer Research, 2021, 27, 131-140.	7.0	93
7	Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. BMC Cancer, 2021, 21, 57.	2.6	3
8	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. Clinical Cancer Research, 2021, 27, 2571-2583.	7.0	22
9	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	2.8	57
10	The "Great Debate―at Melanoma Bridge 2020: December, 5th, 2020. Journal of Translational Medicine, 2021, 19, 142.	4.4	1
11	Abstract CT008: Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow up. Cancer Research, 2021, 81, CT008-CT008.	0.9	2
12	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of Clinical Oncology, 2021, 39, 2656-2666.	1.6	145
13	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
14	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 2021, 157, 391-402.	2.8	13
15	Preexisting immuneâ€mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors. Cancer Medicine, 2021, 10, 7457-7465.	2.8	11
16	Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. European Journal of Cancer, 2021, 158, 225-233.	2.8	8
17	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 3978-3992.	1.6	121
18	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	1.6	580

#	Article	IF	CITATIONS
19	390â€A global, molecular disease characterization initiative (MDCI) in oncology clinical trials. , 2021, 9, A423-A423.		0
20	Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. European Journal of Cancer, 2020, 137, 171-174.	2.8	11
21	P865â€Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update. , 2020, , .		3
22	A proposal for score assignment to characterize biological processes from mass spectral analysis of serum. Clinical Mass Spectrometry, 2020, 18, 13-26.	1.9	2
23	Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 1465-1477.	10.7	330
24	TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?. Clinical Cancer Research, 2020, 26, 2085-2086.	7.0	8
25	New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986–2016. American Journal of Public Health, 2020, 110, 731-733.	2.7	91
26	Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy. Frontiers in Immunology, 2020, 11, 164.	4.8	8
27	Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. , 2020, 8, e000842.		126
28	C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. , 2020, 8, e000234.		56
29	Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. , 2020, 8, e000356.		34
30	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
31	Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. Clinical Cancer Research, 2020, 26, 3384-3396.	7.0	24
32	Systemic Therapy for Melanoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 3947-3970.	1.6	190
33	Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies Journal of Clinical Oncology, 2020, 38, 10006-10006.	1.6	32
34	A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies Journal of Clinical Oncology, 2020, 38, 3094-3094.	1.6	5
35	Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors Journal of Clinical Oncology, 2020, 38, TPS3166-TPS3166.	1.6	4
36	Using autoantibody signatures to predict immunotherapy discontinuation in melanoma patients Journal of Clinical Oncology, 2020, 38, 3069-3069.	1.6	0

#	Article	IF	CITATIONS
37	Lack of evidence to support large-panel genomic testing in treatment selection for malignant melanoma Journal of Clinical Oncology, 2020, 38, e22027-e22027.	1.6	0
38	Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma Journal of Clinical Oncology, 2020, 38, 10052-10052.	1.6	4
39	Novel blood-based biomarker predicting severe toxicity in melanoma anti-CTLA-4 immunotherapy treatment Journal of Clinical Oncology, 2020, 38, 3077-3077.	1.6	0
40	Impact of immune checkpoint and BRAF inhibitors on the incidence of second primary malignancies (SPM) in melanoma Journal of Clinical Oncology, 2020, 38, 12061-12061.	1.6	0
41	Using machine learning to predict immunotherapy response in advanced melanoma Journal of Clinical Oncology, 2020, 38, 10010-10010.	1.6	1
42	681â€Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors. , 2020, , .		0
43	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer, 2019, 119, 1-10.	2.8	132
44	Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Medicine, 2019, 11, 61.	8.2	134
45	Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition Journal of Clinical Oncology, 2019, 37, 100-100.	1.6	44
46	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial Journal of Clinical Oncology, 2019, 37, 2512-2512.	1.6	18
47	Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144,) Tj ETQq1 including anti-PD-1 Journal of Clinical Oncology, 2019, 37, 2518-2518.	1 0.784314 rgBT 1.6	/Overlock 71
48	Using machine learning algorithms to predict response and toxicity to immune checkpoint inhibitors (ICIs) in melanoma patients Journal of Clinical Oncology, 2019, 37, 2581-2581.	1.6	3
49	The relationship between obesity and immunotherapy: It's complicated Journal of Clinical Oncology, 2019, 37, 9562-9562.	1.6	4
50	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238) Journal of Clinical Oncology, 2019, 37, 9584-9584.	1.6	6
51	Effects of online education on the identification and management of immune-related adverse events over time Journal of Clinical Oncology, 2019, 37, e18224-e18224.	1.6	2
52	The solved and unresolved issues of melanoma staging: A comparison of American Joint Committee on Cancer (AJCC) 7th versus 8th edition Journal of Clinical Oncology, 2019, 37, 9578-9578.	1.6	0
53	First-line stereotactic radiosurgery combined with systemic targeted and immune checkpoint inhibitor therapy in melanoma patients with newly diagnosed brain metastases Journal of Clinical Oncology, 2019, 37, e13577-e13577	1.6	0
54	Online education about immunotherapy for melanoma: Outcomes over time Journal of Clinical Oncology, 2019, 37, 10533-10533.	1.6	0

#	Article	IF	CITATIONS
55	Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i> V600E-Mutant Melanoma. Clinical Cancer Research, 2018, 24, 5516-5524.	7.0	55
56	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical Cancer Research, 2018, 24, 4960-4967.	7.0	222
57	Recent advances in adjuvant therapy for patients with melanoma. ESMO Open, 2018, 3, e000337.	4.5	Ο
58	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	28.9	113
59	Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma. Cancer, 2018, 124, 2254-2255.	4.1	0
60	Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer, 2018, 124, 297-305.	4.1	76
61	A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma. Cancer Immunology Research, 2018, 6, 79-86.	3.4	61
62	The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunology, Immunotherapy, 2018, 67, 381-392.	4.2	113
63	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 2018, 36, 383-390.	1.6	431
64	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1714-1768.	1.6	2,691
65	Frontiers in pigment cell and melanoma research. Pigment Cell and Melanoma Research, 2018, 31, 728-735.	3.3	10
66	Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Frontiers in Oncology, 2018, 8, 44.	2.8	67
67	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine, 2018, 10, .	12.4	425
68	Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 6236-6247.	7.0	54
69	Immunotherapy in the adjuvant setting for high-risk melanoma. Clinical Advances in Hematology and Oncology, 2018, 16, 546-548.	0.3	1
70	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2017, 18, 393-403.	10.7	91
71	PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunology, Immunotherapy, 2017, 66, 551-564.	4.2	253
72	Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist, 2017, 22, 709-718.	3.7	221

#	Article	IF	CITATIONS
73	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Journal of Clinical Oncology, 2017, 35, 785-792.	1.6	930
74	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine, 2017, 377, 1824-1835.	27.0	1,752
75	Reply to F. Liang et al. Journal of Clinical Oncology, 2017, 35, 1968-1968.	1.6	0
76	Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology, 2017, 35, 139-140.	1.6	22
77	Biomarkers for Checkpoint Inhibition. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 205-209.	3.8	11
78	Association of changes in T regulatory cells (Treg) during nivolumab treatment with melanoma outcome Journal of Clinical Oncology, 2017, 35, 3031-3031.	1.6	3
79	Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600–mutant unresectable or metastatic melanoma (MM) Journal of Clinical Oncology, 2017, 35, 9505-9505.	1.6	7
80	Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL) Journal of Clinical Oncology, 2017, 35, 9523-9523.	1.6	18
81	A phase I trial of panobinostat with ipilimumab in advanced melanoma Journal of Clinical Oncology, 2017, 35, 9547-9547.	1.6	12
82	Final report of a pilot trial combining ipilimumab and adoptive cell therapy Journal of Clinical Oncology, 2017, 35, 147-147.	1.6	1
83	Evaluation of an online tool providing management guidance for adverse events associated with immune checkpoint inhibitors Journal of Clinical Oncology, 2017, 35, e18131-e18131.	1.6	0
84	Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response Journal of Clinical Oncology, 2017, 35, 3017-3017.	1.6	0
85	Association of distinct baseline tissue biomarkers with response to nivolumab (NIVO) and ipilimumab (IPI) in melanoma: CheckMate 064 Journal of Clinical Oncology, 2017, 35, 9515-9515.	1.6	1
86	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	4.5	82
87	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	7.4	857
88	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855.	27.0	1,140
89	Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Oncologist, 2016, 21, 1230-1240.	3.7	212
90	Clinical outcomes in metastatic uveal melanoma treated with PDâ€1 and PDâ€11 antibodies. Cancer, 2016, 122, 3344-3353.	4.1	288

6

#	Article	IF	CITATIONS
91	A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. , 2016, 4, 85.		18
92	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2016, 17, 943-955.	10.7	293
93	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology, 2016, 34, 1510-1517.	1.6	627
94	Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clinical Cancer Research, 2016, 22, 886-894.	7.0	705
95	Modeling the cost of immune checkpoint inhibitor-related toxicities Journal of Clinical Oncology, 2016, 34, 6627-6627.	1.6	11
96	Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Journal of Clinical Oncology, 2016, 34, 9503-9503.	1.6	98
97	Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM) Journal of Clinical Oncology, 2016, 34, 9507-9507.	1.6	5
98	Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064) Journal of Clinical Oncology, 2016, 34, 9517-9517.	1.6	1
99	Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL) Journal of Clinical Oncology, 2016, 34, 9525-9525.	1.6	2
100	Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma Journal of Clinical Oncology, 2016, 34, 9544-9544.	1.6	2
101	Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL) Journal of Clinical Oncology, 2016, 34, 9586-9586.	1.6	10
102	Selective histone deacetylase inhibition augments melanoma immunotherapy Journal of Clinical Oncology, 2016, 34, e14521-e14521.	1.6	1
103	In vitro and in vivo anti-melanoma activity of ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties Journal of Clinical Oncology, 2016, 34, e21075-e21075.	1.6	2
104	ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors Journal of Clinical Oncology, 2016, 34, TPS3107-TPS3107.	1.6	13
105	Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget, 2016, 7, 23885-23896.	1.8	23
106	Epigenetic control of CD4/CD8 lineage commitment and resistance to tumor infiltrating lymphocyte adoptive cell therapy for metastatic melanoma Journal of Clinical Oncology, 2016, 34, 3008-3008.	1.6	0
107	Toxicities of Immunotherapy for the Practitioner. Journal of Clinical Oncology, 2015, 33, 2092-2099.	1.6	521
108	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 375-384.	10.7	2,353

#	Article	IF	CITATIONS
109	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology, 2015, 33, 278-284.	1.6	102
110	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, 1889-1894.	1.6	1,809
111	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC) Tj ETQq1 1	0.784314 10.7	rgBT /Overle
112	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, The, 2014, 384, 1109-1117.	13.7	1,588
113	Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma. New England Journal of Medicine, 2013, 369, 134-144.	27.0	3,128
114	Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. Journal of Clinical Oncology, 2012, 30, 2691-2697.	1.6	1,272
115	Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma. Clinical Cancer Research, 2011, 17, 896-906.	7.0	185
116	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 711-723.	27.0	13,065
117	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma. Clinical Cancer Research, 2009, 15, 5591-5598.	7.0	531
118	Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunology, Immunotherapy, 2009, 58, 823-830.	4.2	216
119	Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2008, 26, 5950-5956.	1.6	442
120	Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma. Journal of Clinical Oncology, 2005, 23, 741-750.	1.6	433